Lonza and ABL Bio Collaborate on Bispecific Antibody Product

Lonza announced on April 4, 2023 an agreement with ABL Bio, a Korean biologics company with a focus on bispecific antibodies for immune-oncology and neurodegenerative diseases. The collaboration agreement between the two companies supports the development and manufacturing of ABL Bio’s new bispecific antibody product.

Under the agreement, Lonza will provide ABL Bio with an end-to-end solution and an integrated offering to support the bispecific antibody candidate from DNA to potential investigational new drug (IND) application. ABL Bio will also gain access to Lonza’s DNA-to-IND program, which is designed to support biotech companies in realizing the full potential of bispecific drug candidates, accelerating their path to clinic and developing a robust and scalable manufacturing process.

“With the biologics pipeline evolving towards more complex protein formats, bi- and multi-specific molecules are a growing part of Lonza’s portfolio,” said Jean-Christophe Hyvert, president of biologics, Lonza, in a company press release. “For more than 35 years, our teams have built extensive experience and capabilities in this area, and we are committed to supporting our customers on their unique journey to IND. This collaboration will provide ABL Bio with greater flexibility and speed on the path to commercialization. We look forward to working together to bring this innovative therapeutic antibody candidate one step closer to patients.”